US Codex
Pub. L.
Notes

Title II — Treatment

119th Congress · Approved Dec 1, 2025 · 139 Stat. 669 · Lineage

TITLE II Treatment

SEC. 201. Residential Treatment Program for Pregnant and Postpartum Women.

Section 508 of the Public Health Service Act (42 U.S.C. 290bb–1) is amended—
(1)
in subsection (d)(11)(C), by striking “ providing health services” and inserting “ providing health care services”;
(2)
in subsection (g)—
(A)
by inserting “ a plan describing” after “ will provide”; and
(B)
by adding at the end the following: “ Such plan may include a description of how such applicant will target outreach to women disproportionately impacted by maternal substance use disorder.”; and
(3)
in subsection (s), by striking “ $29,931,000 for each of fiscal years 2019 through 2023” and inserting “ $38,931,000 for each of fiscal years 2026 through 2030”.

SEC. 202. Improving Access to Addiction Medicine Providers.

Section 597 of the Public Health Service Act (42 U.S.C. 290ll) is amended—
(1)
in subsection (a)(1), by inserting “ diagnosis,” after “ related to”; and
(2)
in subsection (b), by inserting “ addiction medicine,” after “ psychiatry,”.

SEC. 203. Mental and Behavioral Health Education and Training Grants.

Section 756(f) of the Public Health Service Act (42 U.S.C. 294e–1(f)) is amended by striking “ fiscal years 2023 through 2027” and inserting “ fiscal years 2026 through 2030”.

SEC. 204. Loan Repayment Program for Substance Use Disorder Treatment Workforce.

Section 781(j) of the Public Health Service Act (42 U.S.C. 295h(j)) is amended by striking “ $25,000,000 for each of fiscal years 2019 through 2023” and inserting “ $40,000,000 for each of fiscal years 2026 through 2030”.

SEC. 205. Development and Dissemination of Model Training Programs for Substance Use Disorder Patient Records.

Section 7053 of the SUPPORT for Patients and Communities Act (42 U.S.C. 290dd–2 note) is amended by striking subsection (e).

SEC. 206. Task Force on Best Practices for Trauma-Informed Identification, Referral, and Support.

Section 7132 of the SUPPORT for Patients and Communities Act (Public Law 115–271; 132 Stat. 4046) is amended—
(1)
in subsection (b)(1)—
(A)
by redesignating subparagraph (CC) as subparagraph (DD); and
(B)
by inserting after subparagraph (BB) the following:

“(CC) The Administration for Community Living.”

(2)
in subsection (d)(1), in the matter preceding subparagraph (A), by inserting “ , developmental disability service providers” before “ , individuals who are”; and
(3)
in subsection (i), by striking “ 2023” and inserting “ 2030”.

SEC. 207. Grants to Enhance Access to Substance Use Disorder Treatment.

Section 3203 of the SUPPORT for Patients and Communities Act (21 U.S.C. 823 note) is amended—
(1)
by striking subsection (b); and
(2)
by striking “ (a) In General.—The Secretary” and inserting the following: “ The Secretary”.

SEC. 208. State Guidance Related to Individuals with Serious Mental Illness and Children with Serious Emotional Disturbance.

(a)
Review of Use of Certain Funding.— Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Assistant Secretary for Mental Health and Substance Use, shall conduct a review of State use of funds made available under the Community Mental Health Services Block Grant program under subpart I of part B of title XIX of the Public Health Service Act (42 U.S.C. 300x et seq.) (referred to in this section as the “block grant program”) for first episode psychosis activities. Such review shall consider the following:
(1)
How States use funds for evidence-based treatments and services according to the standard of care for individuals with early serious mental illness and children with a serious emotional disturbance.
(2)
The percentages of the State funding under the block grant program expended on early serious mental illness and first episode psychosis, and the number of individuals served under such funds.
(b)
Report and Guidance.—
(1)
Report.— Not later than 180 days after the completion of the review under subsection (a), the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report describing—
(A)
the findings of the review under subsection (a); and
(B)
any recommendations for changes to the block grant program that would facilitate improved outcomes for individuals with serious mental illness and children with serious emotional disturbance.
(2)
Guidance.— Not later than 1 year after the date on which the report is submitted under paragraph (1), the Secretary shall update the guidance provided to States under the block grant program on coordinated specialty care and other evidence-based mental health care services for individuals with serious mental illness and children with a serious emotional disturbance, based on the findings and recommendations of such report.

SEC. 209. Reviewing the Scheduling of Approved Products Containing a Combination of Buprenorphine and Naloxone.

(a)
Secretary of HHS.— The Secretary of Health and Human Services shall, consistent with the requirements and procedures set forth in sections 201 and 202 of the Controlled Substances Act (21 U.S.C. 811, 812)—
(1)
review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); and
(2)
if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products.
(b)
Attorney General.— The Attorney General shall review any request made by the Secretary of Health and Human Services under subsection (a)(2) and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections 201 and 202 of the Controlled Substances Act (21 U.S.C. 811, 812).

SEC. 210. References to Opioid Overdose Reversal Agents in Hhs Grant Programs.

(a)
In General.— The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for emergency treatment of a known or suspected opioid overdose.
(b)
Existing References.—
(1)
Update.— Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
(2)
References.— A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
(A)
was issued before the date of enactment of this Act; and
(B)
is included in—
(i)
the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (42 U.S.C. 290ee–3 note) (commonly referred to as “State Opioid Response Grants” and “Tribal Opioid Response Grants”); or
(ii)
the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (42 U.S.C. 290bb–22).

SEC. 211. Roundtable on Using Health Information Technology to Improve Mental Health and Substance Use Care Outcomes.

(a)
Roundtable.— Not later than 180 days after the date of enactment of this Act, the National Coordinator for Health Information Technology shall convene a public roundtable to examine—
(1)
how the expanded use of electronic health records among mental health and substance use service providers can improve outcomes for patients in mental health and substance use settings; and
(2)
how best to increase electronic health record adoption among such providers.
(b)
Participants.— The National Coordinator for Health Information Technology shall ensure that the participants in the roundtable under subsection (a) include private and public sector stakeholders, including patients, providers (including providers of inpatient services and providers of outpatient services), and representatives of payors, health information exchanges, professional associations, health information technology vendors, health information technology certification organizations, and State and Federal agencies.
(c)
Report.— Not later than 180 days after the conclusion of the public stakeholder roundtable under subsection (a), the National Coordinator for Health Information Technology shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report outlining information gathered from the roundtable under subsection (a). Such report shall include an examination of—
(1)
recommendations from the roundtable participants;
(2)
unique considerations for using electronic health record systems in mental health and substance use treatment settings;
(3)
unique considerations for developers of health information technology relating to certification of electronic health record systems for use in mental health and substance use treatment settings where the applicable health information technology is not subject to certification requirements;
(4)
current usage of electronic health record systems by mental health and substance use disorder service providers, and the scope and magnitude of such providers that do not use electronic health record systems;
(5)
examples of how electronic health record systems enable coordinated care and care management;
(6)
how electronic health record systems advance appropriate patient and provider access to secure, usable electronic information exchange;
(7)
how electronic health record systems can be connected to or support existing systems, which may include the 9–8–8 National Suicide Prevention Lifeline, mobile crisis response systems, and co-responder programs, to facilitate connectivity, response, and integrated care;
(8)
any existing programs to support greater adoption of electronic health record systems among mental health and substance use service providers;
(9)
any limitations to greater adoption of electronic health record systems among mental health and substance use service providers;
(10)
the costs of adoption of electronic health record systems by mental health and substance use disorder service providers; and
(11)
best practices implemented by States and other entities to support adoption of use of electronic health records among mental health and substance use disorder service providers.